Lucid Diagnostics Q1 2026: Processed 3,177 EsoGuard tests, revenue $1.3M, net loss $23.6M

Lucid Diagnostics Inc.

Processed 3,177 EsoGuard tests in Q1, generating $1.3M in revenue; operating expenses $13.4M including $1.4M stock comp.
GAAP net loss attributable to common stockholders $23.6M ($0.17 per share); non-GAAP adjusted loss $10.5M ($0.07 per share).
Ended Q1 with $27.9M cash; proforma cash $45M after $17M public offering, extending runway into 2027.
Expects Medicare coverage as key milestone; preview of upcoming guideline update recommending EsoGuard as only non-endoscopic test.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.